搜索临床试验以:ZSP1273 中值剂量
总计11419个结果
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.完全的
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.未知
-
University of South CarolinaMedical University of South Carolina; National Institute on Deafness and Other Communication...完全的
-
Guangdong Raynovent Biotech Co., Ltd完全的
-
Astellas Pharma Inc终止未接受过 EGFR-TKI 治疗且携带 EGFR 激活突变的 NSCLC 患者日本
-
Jiangsu Province Centers for Disease Control and...Academy of Military Medical Sciences,Academy of Military Sciences,PLA; ZHONGYIANKE Biotech Co... 和其他合作者招聘中
-
Matthew EagletonMassachusetts General Hospital邀请报名主动脉夹层 | 升主动脉夹层 | 胸腹主动脉瘤 | 胸主动脉瘤 | 解剖,动脉瘤 | 升主动脉瘤 | 主动脉弓;动脉瘤,解剖 | 肾动脉瘤 | 肠系膜上动脉瘤美国
-
Carmel Medical CenterTechnion, Israel Institute of Technology完全的
-
Carmel Medical CenterTechnion, Israel Institute of Technology完全的
-
University of the West of EnglandUniversity of Hawaii; Indonesia University; Unilever R&D; UNICEF完全的
-
University of Southern CaliforniaNational Institutes of Health (NIH)撤销
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)完全的
-
OSE Immunotherapeutics招聘中溃疡性结肠炎比利时, 拉脱维亚, 保加利亚, 白俄罗斯, 克罗地亚, 乔治亚州, 匈牙利, 波兰, 俄罗斯联邦, 南非, 乌克兰
-
Astellas Pharma Global Development, Inc.撤销具有 EGFR 激活突变的 NSCLC 受试者
-
Astellas Pharma Global Development, Inc.终止
-
Astellas Pharma Global Development, Inc.撤销实体瘤 | 表皮生长因子受体 (EGFR) 突变
-
Northwestern UniversityWomen and Infants Hospital of Rhode Island招聘中
-
Women's College HospitalRyerson University撤销